(E) Today, Moderna announced the results of its phase 3 study, and gave some additional details about its vaccine.

Moderna vaccine is slightly more efficient than the one from BioNTech, 94% vs 90%, can be stored between 2 and 8 degrees Celsius versus BioNTech below -70 degrees Celsius.

By the end of the year, Moderna expects to have approximately 20 million doses of its vaccine ready to ship in the U.S., and to manufacture 500 million to 1 billion doses globally in 2021.

Pfizer and BioNTech expect to manufacture up to 100 million doses by the end of 2020, and potentially more than 1.3 billion doses by the end of 2021.

Following is Moderna CEO’s Stéphane Bancel interviewed by CNBC:

References

• “Understanding mRNA COVID-19 Vaccines“, CDC
• Corbett, K.S., Edwards, D.K., Leist, S.R. et al., “SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness“, Nature
• Covid-19 – Day 361: BioNTech and Pfizer Vaccine for the SARS-CoV-2, A Silicon Valley Insider
• COVID-19 – Day 120: First Trial of COVID-19 Vaccine with Humans, A Silicon Valley Insider

Note: The picture above is a vaccination.

Copyright © 2005-2020 by Serge-Paul Carrasco. All rights reserved.
Contact Us: asvinsider at gmail dot com